It remains ThromboGenics' intention that it will only move forward with the development of microplasmin for the treatment of stroke in cooperation with a partner. This view is based on both the risks and cost associated with the development of new stroke therapies, and the Company's desire to invest in its other attractive pipeline product candidates, including microplasmin in the treatment of back of the eye diseases.
ThromboGenics partner for the clinical development and commercialization of THR-100, Bharat Biotech, continues to work with the Indian authorities to gain the necessary approvals to begin a Phase III trial with this novel variant of Recombinant Staphylokinase. The initial trial will evaluate THR-100 for the treatment of acute myocardial infarction (AMI), or heart attack. Given the commercial strengths of Bharat in this market and the clinical advantages of THR-100, it is hoped that this novel product will quickly become the market leader for the thrombolytic treatment of heart attacks in India.
TB-403 - Working with Roche on this Potential Breakthrough Cancer Treatment
ThromboGenics, in conjunction with its partner BioInvent, has made good progress in transferring this novel anti-cancer agent to Roche following the strategic alliance signed in June 2008.
Following the successful completion of the initial Phase I study, the
parties have begun a Phase Ib trial with TB-403 in end-stage cancer
patients. This study, which will recruit approximately 24 patients, is
designed to provide both safety data on TB-403 when used in cancer patients
|SOURCE ThromboGenics NV|
Copyright©2008 PR Newswire.
All rights reserved